CLCN2 and leukodystrophy: Taken together, as emphasized in the schematic model illustrated in Figure 10, our findings highlight the therapeutic potential of 17-AAG and MLN4924 as clinically applicable small molecules for correcting impaired ER proteostasis of leukodystrophy-causing, loss-of-function ClC-2 mutant proteins.